Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Abbott has reported new data from its Volt CE Mark Study in individuals treated with PFA therapy using the Volt PFA System ...

SGLT2 inhibitors, compared with GLP1 agonists, significantly lower risk for atrial fibrillation in patients with type 2 diabetes.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Dr. Paul Dorian, MD, CM, MSc., Cardiologist, discusses atrial fibrillation treatment options.

Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

Atrial fibrillation remains a common and challenging cardiac arrhythmia, particularly in hypertensive patients, who face a ...

Today, the Heart Rhythm Society (HRS) released a framework outlining criteria for establishing an Atrial Fibrillation (AF) ...